Circulating Tumor Cell Count Reliable in Determining Best Treatment Approach for Metastatic Breast Cancer
Circulating tumor cell count is a reliable biomarker for choosing between chemotherapy or endocrine therapy for patients with HER2-negative metastatic breast cancer, according to a recent study published in JAMA Oncology (2020 Nov 5. doi:10.1001/jamaoncol.2020.5660).
“The choice between chemotherapy and endocrine therapy as first-line treatment for [HER2-negative] metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis,” wrote François-Clément Bidard, MD, PhD, Department of Medical Oncology, Institut Curie, Saint-Cloud, France, and colleagues.